Navigation Links
SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
Date:11/4/2008

ProStrakan's First U.S. Product Will Be Sold by A Uniquely-Trained Sales

Force

BEDMINSTER, N.J., Nov. 4 /PRNewswire-FirstCall/ -- ProStrakan Group plc (LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System) is now available by prescription for patients with chemotherapy-induced nausea and vomiting (CINV) in the United States. Sancuso was approved by the U.S. Food and Drug Administration (F.D.A.) in September 2008 as the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen.

"Chemotherapy-induced nausea and vomiting is one of the most feared side effects of chemotherapy, often times forcing patients to stop important cancer treatments," said company CEO Wilson Totten, MD. "Now, with the availability of Sancuso, healthcare practitioners, patients and caregivers have a new tool in their toolbox to prevent the debilitating side effects of CINV."

Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established preventor of nausea and vomiting, through a thin layer of adhesive that attaches the patch to the skin on the upper outer arm. The medicine is then released slowly and continuously into the bloodstream for up to five consecutive days.

"As a company dedicated to the needs of the patients, we are thrilled to be launching our first product in the U.S.," added Totten. "The ability to successfully bring Sancuso to the oncology community opens doors for us to introduce other supportive oncology care products, particularly those designed for easier patient use."

A Distinctive Sales Force

In order to better meet the needs of patients and oncology health-care professionals, the Sancuso sales force has been trained by oncology nurses through a partnership with ONSEdge(R), a subsidiary of the Oncology Nursing Society. Each member of the sales force participated in a detailed training program administered by oncology nurses, which focused on both general oncology and CINV.

"We believe that the best way to understand and appreciate the needs of health-care providers is to be trained by them. As a result of our collaboration with ONSEdge, our sales force is well-prepared to discuss SANCUSO in a responsible way and in a manner that will better serve the community at large," said Totten.

ProStrakan's robust 67-person sales force in the U.S. was hired in partnership with NovaQuest, the managed partnership group of Quintiles Transnational.

Additionally, as part of the company's ongoing commitment, ProStrakan has developed a patient assistance program to ensure that Sancuso is available to any qualified patients who would benefit from it. Please visit http://www.Sancuso.com for additional information. The company is also working with regulatory authorities to bring Sancuso to market in Europe.

About CINV

Chemotherapy-induced nausea and vomiting (CINV) are commonly cited by patients undergoing chemotherapy as highly feared side effects. In addition to its social and emotional effects, if left untreated, CINV can lead to dehydration, malnutrition, treatment delay, or even discontinuation of treatment. Despite advances in treatment, CINV remains a significant problem. Some patients expect to endure unpleasant symptoms in order to continue chemotherapy and may suffer at home while not under the supervision of a health-care professional. With one application of Sancuso, patients receive up to five consecutive days of CINV treatment.

Important Safety Information About SANCUSO(R)

Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.

Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition. Mild application site reactions have occurred; remove patch if severe reactions or a generalized skin reaction occur. Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.

The most common adverse reaction is constipation. No clinically relevant drug interactions have been reported in clinical studies with Sancuso.

About ProStrakan

ProStrakan is one of Europe's fastest growing pharmaceutical companies, with new U.S. headquarters in Bedminster, New Jersey. ProStrakan is committed to developing innovative therapies to improve the lives of patients. Our current products range from cancer, women's health, men's health, anesthesiology, and cardiovascular disease. For more information on ProStrakan, please visit http://www.ProStrakan-USA.com.


'/>"/>
SOURCE ProStrakan Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... ... , ... Back Pain Centers of America (BPC), which connects people ... their area, announces the launch of a new and proprietary customer relationship management (CRM) ... reputable physicians to help them with back or neck pain and helps to match ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... analytics to its patient care management module. Using this new feature, sleep physicians ... has been initiated on continuous positive airway pressure (CPAP), oral, or other forms ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: